Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Zomedica Stock Surged Today

By Joe Tenebruso - Jan 12, 2021 at 12:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why you may want to consider selling your shares now.

What happened

Shares of Zomedica Pharmaceuticals ( ZOM -4.97% ) continued their recent rapid ascent on Tuesday. As of 11:33 a.m. EST, the veterinary health company's stock price is up more than 40%.

So what 

Excitement may be building for the upcoming launch of Zomedica's point-of-care diagnostic platform for pets on March 30. The company says its patented system can help detect thyroid and adrenal disease in cats and dogs. 

"We set out to develop a product that could provide the accuracy of the reference lab and the convenience of point-of-care for the veterinary community," Zomedica chief medical officer Stephanie Morley said in a November press release announcing the launch. "As a vet myself, I know the value of such a product to a veterinary practice."  

A digital stock chart that rises sharply and then begins to fall.

Zomedica's stock is up sharply on Tuesday, but the gains may not last. Image source: Getty Images.

However, it appears that stock promotion schemes may also be contributing to Zomedica's recent price gains. Carole Baskin, star of the popular Netflix show Tiger King, recently appeared in a video on social media speaking favorably about Zomedica. She may have been paid $299 to do so, according to Benzinga. 

Now what

Up until today, Zomedica's stock had been trading for less than $1 per share. Small-cap stocks with low share prices, often referred to as penny stocks, can be highly volatile. Stock promoters can quickly drive up their share prices, but shareholders often suffer brutal losses once promoters move on to other stocks. Thus, investors may want to consider taking profits in Zomedica if they own shares.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
ZOM
$0.36 (-4.97%) $0.02
Netflix, Inc. Stock Quote
Netflix, Inc.
NFLX
$603.46 (-2.11%) $-13.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.